ONCS - OncoSec Medical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6100
+0.0400 (+2.55%)
As of 11:03AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.5700
Open1.5900
Bid1.6000 x 2200
Ask1.6200 x 1800
Day's Range1.5201 - 1.6200
52 Week Range1.5201 - 7.5000
Volume32,027
Avg. Volume109,303
Market Cap36.564M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • OncoSec Strengthens its Board of Directors with Three New Appointments
    PR Newswire

    OncoSec Strengthens its Board of Directors with Three New Appointments

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced changes to its Board of Directors (the "Board") following the closing of the strategic investment by and partnership (the "CGP/Sirtex Transaction") with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP"), and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex").

  • Business Wire

    OncoSec Announces Closing of the CGP/Sirtex Transaction

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that, following shareholder approval, the proposed strategic investment by and partnership (the "CGP/Sirtex Transaction") with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP"), and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex") has closed.

  • Business Wire

    OncoSec Announces that Shareholders Have Approved CGP/Sirtex Transaction

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that, at its Special Meeting of Shareholders (the "Special Meeting"), based on a preliminary vote count provided by the Company’s proxy solicitor, OncoSec shareholders have approved the proposed strategic investment by and partnership (the "CGP/Sirtex Transaction") with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP"), and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex").

  • Business Wire

    OncoSec Announces that Nevada Court Denies Alpha Holdings’ Motion to Enjoin Special Meeting of Shareholders

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today commented on the February 6 ruling from the District Court in Clark County, Nevada, denying Alpha Holdings, Inc.’s ("Alpha") motion to enjoin OncoSec’s Special Meeting of Shareholders (the "Special Meeting") to approve the proposed strategic investment by and partnership (the "CGP/Sirtex Transaction") with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited, and its U.S. affiliate, Sirtex Medical US Holdings, Inc.

  • Clinical Cancer Research highlights OncoSec's Merkel Cell Carcinoma Clinical Study on the Cover of its February Issue
    PR Newswire

    Clinical Cancer Research highlights OncoSec's Merkel Cell Carcinoma Clinical Study on the Cover of its February Issue

    OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of data showing that TAVO™ (plasmid-based interleukin-12) treatment, administered through OncoSec's electroporation gene delivery system, resulted in regression of injected and non-injected Merkel cell carcinoma (MCC) tumors. The study, a pilot with fifteen patients, is featured on the cover of the February issue of Clinical Cancer Research (print edition available here).

  • Business Wire

    Alpha Holdings Urges OncoSec Stockholders to Vote Against China Grand Takeover on BLUE Proxy Card Only

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today issued the following letter to OncoSec stockholders regarding OncoSec’s rejection of Alpha’s renewed binding term sheet, which detailed a superior financing proposal that would have delivered $39.3 million of value compared with the $30 million China Grand Takeover Proposal,1 including the opportunity for stockholders to receive a cash premium for 35% of OncoSec shares through a tender offer of $2.50 per share.

  • OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting
    PR Newswire

    OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting

    OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced data from a feasibility study of its visceral lesion applicator (VLA) electroporation device that were presented at the Annual Meeting of the Society of Interventional Oncology (SIO) in New Orleans. The study, which was awarded "Best Technology Scientific Abstract" at SIO, showed investigators were able to successfully and safely reach target organs located deep inside the body and deploy the device's applicator tip in a large animal model.

  • Business Wire

    OncoSec Urges Shareholders to Focus on the Critical Benefits of CGP/Sirtex Transaction

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today issued the following statement to its shareholders related to the upcoming Special Meeting to vote on the proposed strategic investment by and partnership (the "CGP/Sirtex Transaction") with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP"), and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex"):

  • Business Wire

    OncoSec Urges Shareholders Not to Fall for Alpha’s Disingenuous "Proposal" and Scheme to Prevent Fair Vote at Special Meeting

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today issued the following statement to its shareholders regarding Alpha Holdings, Inc.’s ("Alpha") January 27, 2020 press release:

  • Business Wire

    Alpha Holdings Renews Superior, $39.3 Million Offer to OncoSec

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today announced that it has renewed its alternative financing proposal and provided a revised binding term sheet to OncoSec. Alpha continues to believe its proposed financing is significantly more favorable to OncoSec and its stockholders than the $30 million takeover offer from China Grand.1

  • Data from OncoSec's Visceral Lesion Applicator (VLA) to be Presented at the Society of Interventional Oncology Annual Meeting
    PR Newswire

    Data from OncoSec's Visceral Lesion Applicator (VLA) to be Presented at the Society of Interventional Oncology Annual Meeting

    OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced data from initial feasibility studies of its novel visceral lesion applicator (VLA) have been accepted to be presented at the Annual Meeting of the Society of Interventional Oncology in New Orleans from January 30 - February 3, 2020.

  • Business Wire

    OncoSec Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, announced today the appointment of Robert J. DelAversano, C.P.A., as OncoSec’s Principal Accounting Officer and Controller, effective as of January 30, 2020. Mr. DelAversano will be responsible for preparation of financial statements, as well as other finance-related functions, assuming these responsibilities from Sara M. Bonstein, who will be stepping down from her roles as Chief Financial Officer and Chief Operating Officer to pursue another professional opportunity.

  • Business Wire

    OncoSec Sends Letter Urging Shareholders Not to Be Distracted by Alpha’s Last-Ditch Efforts to Derail CGP/Sirtex Transaction

    Daniel O’Connor, President, Director & CEO of OncoSec Medical Incorporated (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today sent the following letter to shareholders. The full text of the letter and additional information can be found at www.advancingoncosec.com.

  • Business Wire

    Alpha Holdings Comments on OncoSec’s Failure to Consider Superior Financing Proposal

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today issued the following response to OncoSec’s rejection of Alpha’s superior financing proposal, which represents $39.3 million of value compared with the $30 million China Grand Takeover Proposal,1 including the opportunity for stockholders to receive a cash premium for 35% of OncoSec shares through a tender offer of $2.50 per share.

  • Business Wire

    OncoSec Board Rejects Alpha Holdings "Proposal" and Announces New Special Meeting Date

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that its Board of Directors (the "Board") has determined the Alpha Holdings, Inc. ("Alpha") proposal conveying a preliminary financing offer is not in the best interests of all shareholders.

  • Business Wire

    INSERTING and REPLACING Alpha Holdings Sends Open Letter to OncoSec Stockholders Answering Questions on Proposed Financing

    Insert new paragraph after the 1st paragraph under the "ADDITIONAL INFORMATION AND WHERE TO FIND IT" section of the release.

  • Business Wire

    Alpha Holdings Makes Superior, $39.3 Million Offer to OncoSec

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today announced that it has delivered a binding term sheet to the Board of Directors of OncoSec containing a detailed alternative proposal for their consideration.

  • Business Wire

    Alpha Holdings Urges Oncosec Stockholders to Vote Against China Grand Takeover on Blue Proxy Card

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today sent a letter to its fellow OncoSec stockholders in advance of the Company’s upcoming Special Meeting of Stockholders, currently scheduled for January 17, 2020, urging them to vote on the BLUE proxy card "AGAINST" the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand").

  • Business Wire

    OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Have Recommended That OncoSec Shareholders Vote "FOR" the CGP/Sirtex Transaction on the WHITE Proxy Card

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to its shareholders. The full text of the letter and additional information can be found at www.advancingoncosec.com.